Compare FORTY & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | BEAM |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 1997 | 2020 |
| Metric | FORTY | BEAM |
|---|---|---|
| Price | $174.69 | $26.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $48.09 |
| AVG Volume (30 Days) | 602.0 | ★ 2.0M |
| Earning Date | 11-20-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $3,016,039,000.00 | $55,701,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.52 |
| P/E Ratio | $37.72 | ★ N/A |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $80.15 | $13.53 |
| 52 Week High | $176.50 | $35.25 |
| Indicator | FORTY | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 70.07 | 56.13 |
| Support Level | $149.75 | $25.86 |
| Resistance Level | $169.03 | $28.28 |
| Average True Range (ATR) | 2.04 | 1.63 |
| MACD | 2.13 | 0.25 |
| Stochastic Oscillator | 99.19 | 58.35 |
Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources, Michpal, ZAP Group, and Others. The majority of the company's revenue comes from Israel.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.